The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases.
about
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation updateLRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stressGenetics of Progressive Supranuclear PalsyThe genetics and neuropathology of Parkinson's diseaseGlucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson diseaseA common genetic factor for Parkinson disease in ethnic Chinese population in TaiwanTranscriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.Analysis of the LRRK2 G2019S mutation in Alzheimer Disease.Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's diseaseNeurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis.The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activityPrevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.Biomarkers in Parkinson's disease.Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubulesClinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations.Progress in neuroprotection in Parkinson's disease.The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System AtrophyDevelopment of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.Update on the functional biology of Lrrk2.Molecular pathology of Lewy body diseases.Multiple system atrophy: the application of genetics in understanding etiology.Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets.Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges.Modeling Parkinson's disease using induced pluripotent stem cells.Therapeutic strategies in Parkinson's disease: what we have learned from animal models.LRRK2 at the Crossroad Between Autophagy and Microtubule Trafficking: Insights into Parkinson's Disease.Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.Pathological and Clinical Spectrum of Progressive Supranuclear Palsy: With Special Reference to Astrocytic Tau Pathology.Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease.Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism.
P2860
Q22252904-31E70D68-F67C-45A5-A97C-8D14BD7107D7Q24294466-61EEFE57-A64F-48D2-A9BD-D413D663E593Q26785904-F90B0F9C-A05D-446E-804A-655033FE7C86Q26859945-625A2000-03D4-4855-8093-9A657A0A8C59Q30483458-585CA77F-7D7D-4089-8C9B-D80618AA9BB0Q33267533-F09DABF5-C258-4B85-83E5-837348D1795BQ33614776-B5026317-67B6-4B19-BDBF-A0B2C7F5D1B1Q33666090-4524EE0F-D93B-4FF6-90E3-18019D44A574Q33812599-6E10B920-BFF2-4AFE-81CF-4ADAEE84F532Q34079770-C4C5C539-D85C-4A41-A53D-B3DE44E60FC4Q34236070-0313127F-F2E4-454C-B764-934E1858739FQ36154267-9099B2F9-EA0C-4168-9F6A-26D563315A40Q36226461-B0B3BBBE-226C-4570-BB14-AAD7369AB855Q36511295-CEA64C2F-CB92-4288-B30D-077EFD02774AQ36748778-5EAF1038-EE8E-4860-A84B-DB6352105637Q36982616-B7499436-F759-42E2-BA85-20A1A8E3C551Q37081406-47299BE2-7180-4671-ACC7-92B74C3C4B58Q37114112-B17BF513-62B6-4C00-BD3C-F839EE622F82Q37203387-A98AEE83-80B6-45F6-AE20-E5FFD06912F9Q37249125-44EF419F-2F44-438B-A773-BD7CAC648D73Q37395783-F4417BAF-DB5E-4E87-8C05-AC4F221C6905Q37462203-B3CA4714-D0B1-47E6-A878-E9544D0F50C8Q37566673-CAC1D02D-40CB-4FA2-B2E1-19729200F4E3Q37689883-6E07353B-6B4C-4B77-96CB-4D30A7ADBFC0Q37922212-3CB66C02-2AFB-4A99-B2DA-760F4A8FEB5BQ38005912-C9F93802-F682-4A13-B72F-AD49C3021D5DQ38290759-CE97413F-15FA-466B-A147-154DE17A5BF1Q38689010-F4FB8A77-2692-402F-8021-14E7254D130DQ47161677-FA6AB358-4390-49B7-9E63-4DF653A91010Q48177425-DE65A1B9-39A0-4E1D-B84B-3D7CAFC3AA98Q48252870-290BAD9A-E843-4B24-A759-F56D5E723AA6Q50262835-55BB1210-EFD1-4DF7-9291-5EA43DBC6C2A
P2860
The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@ast
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@en
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@nl
type
label
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@ast
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@en
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@nl
prefLabel
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@ast
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@en
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@nl
P2093
P50
P1433
P1476
The dardarin G 2019 S mutation ...... er neurodegenerative diseases.
@en
P2093
Anthony Crawley
Dena Hernandez
Fabienne Wavrant Devrieze
John Werner
Roneil Malkani
P304
P356
10.1016/J.NEULET.2005.07.044
P407
P577
2005-12-01T00:00:00Z